Literature DB >> 19455185

Angelman syndrome (AS, MIM 105830).

Griet Van Buggenhout1, Jean-Pierre Fryns.   

Abstract

Angelman syndrome (AS) is a distinct neurogenetic syndrome, first described in 1965. The phenotype is well known in infancy and adulthood, but the clinical features may change with age. The main clinical characteristics include severe mental retardation, epileptic seizures and EEG abnormalilties, neurological problems and distinct facial dysmorphic features. Behavioural problems such as hyperactivity and sleeping problems are reported, although these patients present mostly a happy personality with periods of inappropriate laughter. Different underlying genetic mechanisms may cause AS, with deletion of chromosome 15 as the most frequent cause. Other genetic mechanisms such as paternal uniparental disomy, imprinting defect and mutation in the UBE3A gene are present in smaller groups of patients with AS. As the recurrence risk can be up to 50%, the clinical diagnosis of AS should be confirmed by laboratory tesing, and genetic counselling should be provided. Treatment of seizures, physical therapy or other intervention strategies are helpful to ameliorate the symptoms.

Entities:  

Mesh:

Year:  2009        PMID: 19455185      PMCID: PMC2986680          DOI: 10.1038/ejhg.2009.67

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  42 in total

1.  Clinical research on Angelman syndrome in the United Kingdom: observations on 82 affected individuals.

Authors:  J Clayton-Smith
Journal:  Am J Med Genet       Date:  1993-04-01

Review 2.  Clinical features in 27 patients with Angelman syndrome resulting from DNA deletion.

Authors:  A Smith; C Wiles; E Haan; J McGill; G Wallace; J Dixon; R Selby; A Colley; R Marks; R J Trent
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

Review 3.  Angelman syndrome: clinical profile.

Authors:  R T Zori; J Hendrickson; S Woolven; E M Whidden; B Gray; C A Williams
Journal:  J Child Neurol       Date:  1992-07       Impact factor: 1.987

4.  Angelman syndrome due to paternal uniparental disomy of chromosome 15: a milder phenotype?

Authors:  A Bottani; W P Robinson; C D DeLozier-Blanchet; E Engel; M A Morris; B Schmitt; L Thun-Hohenstein; A Schinzel
Journal:  Am J Med Genet       Date:  1994-05-15

5.  Somatic mosaicism in patients with Angelman syndrome and an imprinting defect.

Authors:  Hülya Nazlican; Michael Zeschnigk; Uwe Claussen; Susanne Michel; Stefan Boehringer; Gabriele Gillessen-Kaesbach; Karin Buiting; Bernhard Horsthemke
Journal:  Hum Mol Genet       Date:  2004-09-22       Impact factor: 6.150

6.  Seizure and EEG patterns in Angelman's syndrome.

Authors:  F Viani; A Romeo; M Viri; M Mastrangelo; F Lalatta; A Selicorni; G Gobbi; G Lanzi; D Bettio; V Briscioli
Journal:  J Child Neurol       Date:  1995-11       Impact factor: 1.987

7.  Chromosome 15 uniparental disomy is not frequent in Angelman syndrome.

Authors:  J H Knoll; K A Glatt; R D Nicholls; S Malcolm; M Lalande
Journal:  Am J Hum Genet       Date:  1991-01       Impact factor: 11.025

8.  Epilepsy in Angelman syndrome associated with chromosome 15q deletion.

Authors:  A Matsumoto; T Kumagai; K Miura; S Miyazaki; C Hayakawa; T Yamanaka
Journal:  Epilepsia       Date:  1992 Nov-Dec       Impact factor: 5.864

9.  Cortical myoclonus in Angelman syndrome.

Authors:  R Guerrini; T M De Lorey; P Bonanni; A Moncla; C Dravet; G Suisse; M O Livet; M Bureau; P Malzac; P Genton; P Thomas; F Sartucci; P Simi; J M Serratosa
Journal:  Ann Neurol       Date:  1996-07       Impact factor: 10.422

10.  Angelman syndrome: consensus for diagnostic criteria. Angelman Syndrome Foundation.

Authors:  C A Williams; H Angelman; J Clayton-Smith; D J Driscoll; J E Hendrickson; J H Knoll; R E Magenis; A Schinzel; J Wagstaff; E M Whidden
Journal:  Am J Med Genet       Date:  1995-03-27
View more
  28 in total

Review 1.  GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.

Authors:  Raman Sankar
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 2.  Regions of homozygosity and their impact on complex diseases and traits.

Authors:  Chee Seng Ku; Nasheen Naidoo; Shu Mei Teo; Yudi Pawitan
Journal:  Hum Genet       Date:  2010-11-23       Impact factor: 4.132

Review 3.  Epigenetics, autism spectrum, and neurodevelopmental disorders.

Authors:  Sampathkumar Rangasamy; Santosh R D'Mello; Vinodh Narayanan
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

4.  Recurrence of Angelman syndrome in siblings: challenges in genetic counseling.

Authors:  Dhanya Yesodharan; M V Thampi; Teena Koshy; Sheela Nampoothiri
Journal:  Indian J Pediatr       Date:  2013-11-28       Impact factor: 1.967

5.  Prader-Willi and Angelman syndromes: genetic counseling.

Authors:  Cristina Camprubí; Maria Dolors Coll; Elisabeth Gabau; Míriam Guitart
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

6.  Do the physiotherapy results make us happy in a case with 'happy puppet' (Angelman) syndrome?

Authors:  Ozgun Kaya Kara; Akmer Mutlu; Mintaze Kerem Gunel; Goknur Haliloglu
Journal:  BMJ Case Rep       Date:  2010-12-29

7.  An atypical case of hypomethylation at multiple imprinted loci.

Authors:  Emma L Baple; Rebecca L Poole; Sahar Mansour; Catherine Willoughby; I Karen Temple; Louise E Docherty; Rohan Taylor; Deborah J G Mackay
Journal:  Eur J Hum Genet       Date:  2011-01-05       Impact factor: 4.246

Review 8.  Clinical review of genetic epileptic encephalopathies.

Authors:  Grace J Noh; Y Jane Tavyev Asher; John M Graham
Journal:  Eur J Med Genet       Date:  2012-01-25       Impact factor: 2.708

Review 9.  [Anesthesia and Angelman syndrome].

Authors:  W Witte; C Nobel; J Hilpert
Journal:  Anaesthesist       Date:  2011-03-16       Impact factor: 1.041

10.  Angelman syndrome in adulthood.

Authors:  Anna M Larson; Julianna E Shinnick; Elias A Shaaya; Elizabeth A Thiele; Ronald L Thibert
Journal:  Am J Med Genet A       Date:  2014-11-26       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.